VGT-309

Showing 1 posts of 1 posts found.

Vergent Bioscience shares phase 2 data for VGT-309

January 29, 2024
Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer

Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …

Latest content